JP2018537501A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018537501A5 JP2018537501A5 JP2018531479A JP2018531479A JP2018537501A5 JP 2018537501 A5 JP2018537501 A5 JP 2018537501A5 JP 2018531479 A JP2018531479 A JP 2018531479A JP 2018531479 A JP2018531479 A JP 2018531479A JP 2018537501 A5 JP2018537501 A5 JP 2018537501A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- disease
- compound according
- ring
- sulfur
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 12
- 239000000203 mixture Substances 0.000 claims 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 239000001301 oxygen Substances 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 239000011593 sulfur Substances 0.000 claims 4
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 claims 3
- 102100039390 Toll-like receptor 7 Human genes 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 2
- 208000025487 periodic fever syndrome Diseases 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 208000007815 Acquired Hyperostosis Syndrome Diseases 0.000 claims 1
- 208000026326 Adult-onset Still disease Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000005024 Castleman disease Diseases 0.000 claims 1
- 206010008690 Chondrocalcinosis pyrophosphate Diseases 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 241001481833 Coryphaena hippurus Species 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 201000005569 Gout Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 102100026018 Interleukin-1 receptor antagonist protein Human genes 0.000 claims 1
- 101710144554 Interleukin-1 receptor antagonist protein Proteins 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 1
- 208000005777 Lupus Nephritis Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 201000004854 SAPHO syndrome Diseases 0.000 claims 1
- 201000010848 Schnitzler Syndrome Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 125000001931 aliphatic group Chemical group 0.000 claims 1
- 239000012472 biological sample Substances 0.000 claims 1
- 208000002849 chondrocalcinosis Diseases 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021019843A JP7317878B2 (ja) | 2015-12-17 | 2021-02-10 | 多環式ｔｌｒ７／８アンタゴニスト及び免疫障害の治療におけるそれらの使用 |
| JP2023117597A JP2023126574A (ja) | 2015-12-17 | 2023-07-19 | 多環式ｔｌｒ７／８アンタゴニスト及び免疫障害の治療におけるそれらの使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562268765P | 2015-12-17 | 2015-12-17 | |
| US62/268,765 | 2015-12-17 | ||
| US201662353603P | 2016-06-23 | 2016-06-23 | |
| US62/353,603 | 2016-06-23 | ||
| PCT/US2016/067112 WO2017106607A1 (en) | 2015-12-17 | 2016-12-16 | Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021019843A Division JP7317878B2 (ja) | 2015-12-17 | 2021-02-10 | 多環式ｔｌｒ７／８アンタゴニスト及び免疫障害の治療におけるそれらの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018537501A JP2018537501A (ja) | 2018-12-20 |
| JP2018537501A5 true JP2018537501A5 (enExample) | 2020-01-30 |
| JP6882299B2 JP6882299B2 (ja) | 2021-06-02 |
Family
ID=58191545
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018531479A Active JP6882299B2 (ja) | 2015-12-17 | 2016-12-16 | 多環式ｔｌｒ７／８アンタゴニスト及び免疫障害の治療におけるそれらの使用 |
| JP2021019843A Active JP7317878B2 (ja) | 2015-12-17 | 2021-02-10 | 多環式ｔｌｒ７／８アンタゴニスト及び免疫障害の治療におけるそれらの使用 |
| JP2023117597A Pending JP2023126574A (ja) | 2015-12-17 | 2023-07-19 | 多環式ｔｌｒ７／８アンタゴニスト及び免疫障害の治療におけるそれらの使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021019843A Active JP7317878B2 (ja) | 2015-12-17 | 2021-02-10 | 多環式ｔｌｒ７／８アンタゴニスト及び免疫障害の治療におけるそれらの使用 |
| JP2023117597A Pending JP2023126574A (ja) | 2015-12-17 | 2023-07-19 | 多環式ｔｌｒ７／８アンタゴニスト及び免疫障害の治療におけるそれらの使用 |
Country Status (29)
| Country | Link |
|---|---|
| US (7) | US10399957B2 (enExample) |
| EP (3) | EP3889146A1 (enExample) |
| JP (3) | JP6882299B2 (enExample) |
| KR (2) | KR20250043596A (enExample) |
| CN (2) | CN108699032B (enExample) |
| AU (4) | AU2016371014B2 (enExample) |
| CA (1) | CA3005766A1 (enExample) |
| CL (1) | CL2018001624A1 (enExample) |
| DK (1) | DK3889145T3 (enExample) |
| ES (2) | ES2981114T3 (enExample) |
| FI (1) | FI3889145T3 (enExample) |
| HR (1) | HRP20240355T1 (enExample) |
| HU (1) | HUE066591T2 (enExample) |
| IL (4) | IL279751B (enExample) |
| LT (1) | LT3889145T (enExample) |
| MX (2) | MX2021006804A (enExample) |
| MY (2) | MY196319A (enExample) |
| NZ (1) | NZ742476A (enExample) |
| PH (1) | PH12018501068A1 (enExample) |
| PL (1) | PL3889145T3 (enExample) |
| PT (1) | PT3889145T (enExample) |
| RS (1) | RS65319B1 (enExample) |
| SG (2) | SG10202001146PA (enExample) |
| SI (1) | SI3889145T1 (enExample) |
| SM (1) | SMT202400141T1 (enExample) |
| TW (3) | TWI804003B (enExample) |
| UA (1) | UA124802C2 (enExample) |
| WO (1) | WO2017106607A1 (enExample) |
| ZA (1) | ZA201803367B (enExample) |
Families Citing this family (114)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY196319A (en) | 2015-12-17 | 2023-03-24 | Merck Patent Gmbh | Polycyclic TLR7/8 Antagonists and use Thereof in the Treatment of Immune Disorders |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| EP3484865B1 (en) | 2016-07-14 | 2022-09-14 | Crinetics Pharmaceuticals, Inc. | Somatostatin modulators and uses thereof |
| CN109563075B (zh) | 2016-08-08 | 2022-09-30 | 默克专利股份公司 | Tlr7/8拮抗剂及其用途 |
| FI3526323T3 (fi) | 2016-10-14 | 2023-06-06 | Prec Biosciences Inc | Hepatiitti B -viruksen genomissa oleville tunnistussekvensseille spesifisiä muokattuja meganukleaaseja |
| WO2018089695A1 (en) * | 2016-11-11 | 2018-05-17 | Dynavax Technologies Corporation | Toll-like receptor antagonist compounds and methods of use |
| CN118894840A (zh) * | 2017-07-18 | 2024-11-05 | 默克专利股份公司 | Tlr7/8拮抗剂及其用途 |
| WO2019089648A1 (en) * | 2017-10-30 | 2019-05-09 | The Regents Of The University Of Colorado, A Body Corporate | Toll-like receptor 8 (tlr8)-specific antagonists and methods of making and uses thereof |
| BR112020012329A2 (pt) | 2017-12-19 | 2020-11-24 | Merck Patent Gmbh | antagonistas de tlr7/8 e usos dos mesmos |
| KR102492115B1 (ko) | 2017-12-20 | 2023-01-27 | 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. | Sting 어댑터 단백질을 활성화하는 포스포네이트 결합을 가진 2'3' 사이클릭 다이뉴클레오티드 |
| CA3084569A1 (en) | 2017-12-20 | 2019-06-27 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| WO2019155042A1 (en) | 2018-02-12 | 2019-08-15 | F. Hoffmann-La Roche Ag | Novel sulfone compounds and derivatives for the treatment and prophylaxis of virus infection |
| US10836769B2 (en) | 2018-02-26 | 2020-11-17 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds and uses thereof |
| US10870691B2 (en) | 2018-04-05 | 2020-12-22 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis B virus protein X |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| US11142750B2 (en) | 2018-04-12 | 2021-10-12 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
| TW202014193A (zh) | 2018-05-03 | 2020-04-16 | 捷克科學院有機化學與生物化學研究所 | 包含碳環核苷酸之2’3’－環二核苷酸 |
| JP7374130B2 (ja) * | 2018-06-05 | 2023-11-06 | エフ． ホフマン－ラ ロシュ アーゲー | 自己免疫疾患治療用の新規なテトラヒドロ－１Ｈ－ピラジノ［２，１－ａ］イソインドリルキノリン化合物 |
| WO2019238616A1 (en) | 2018-06-12 | 2019-12-19 | F. Hoffmann-La Roche Ag | Novel heteroaryl heterocyclyl compounds for the treatment of autoimmune disease |
| WO2019238629A1 (en) * | 2018-06-13 | 2019-12-19 | F. Hoffmann-La Roche Ag | Pyridinyl heterocyclyl compounds for the treatment of autoimmune disease |
| PE20210469A1 (es) | 2018-06-27 | 2021-03-08 | Bristol Myers Squibb Co | Compuestos de naftiridinona sustituidos utiles como activadores de celulas t |
| CN112585139B (zh) | 2018-06-27 | 2023-12-01 | 百时美施贵宝公司 | 用作t细胞激活剂的萘啶酮化合物 |
| KR102651420B1 (ko) * | 2018-07-06 | 2024-03-28 | 길리애드 사이언시즈, 인코포레이티드 | 치료 헤테로시클릭 화합물 |
| US20220363667A1 (en) * | 2018-07-17 | 2022-11-17 | Nippon Chemiphar Co., Ltd. | T-type calcium channel blocker |
| EP3826724B1 (en) * | 2018-07-23 | 2022-10-05 | F. Hoffmann-La Roche AG | Novel piperazine compounds for the treatment of autoimmune disease |
| CN112513024A (zh) * | 2018-07-31 | 2021-03-16 | 默克专利股份公司 | Tlr7/8拮抗剂及其用途 |
| WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
| US20210323977A1 (en) | 2018-08-28 | 2021-10-21 | Hoffmann-La Roche Inc. | Pyrrolidinyl amide compounds for the treatment of autoimmune disease |
| CN112638908A (zh) * | 2018-09-04 | 2021-04-09 | 豪夫迈·罗氏有限公司 | 用于治疗自身免疫性疾病的苯并噻唑类化合物 |
| EP3847173B1 (en) | 2018-09-06 | 2023-04-12 | F. Hoffmann-La Roche AG | Novel pyrazolopyridine compounds for the treatment of autoimmune disease |
| WO2020048595A1 (en) * | 2018-09-06 | 2020-03-12 | F. Hoffmann-La Roche Ag | Novel cyclic amidine compounds for the treatment of autoimmune disease |
| WO2020048605A1 (en) * | 2018-09-07 | 2020-03-12 | F. Hoffmann-La Roche Ag | Novel pyrrolidine amine compounds for the treatment of autoimmune disease |
| CN112673007A (zh) * | 2018-09-11 | 2021-04-16 | 豪夫迈·罗氏有限公司 | 用于治疗自身免疫性疾病的吡唑并吡啶胺化合物 |
| EP3623369B1 (en) | 2018-09-12 | 2023-10-25 | F. Hoffmann-La Roche AG | Novel morpholinyl amine compounds for the treatment of autoimmune disease |
| JP2022501401A (ja) * | 2018-09-27 | 2022-01-06 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 自己免疫疾患の治療のためのヘテロシクリル化合物 |
| CN109516925B (zh) * | 2018-10-31 | 2021-07-16 | 陕西慧康生物科技有限责任公司 | 一种谷氨酸-1-甲酯-5-叔丁酯的合成方法 |
| HRP20240541T1 (hr) | 2018-10-31 | 2024-07-05 | Gilead Sciences, Inc. | Supstituirani spojevi 6-azabenzimidazola kao inhibitori hpk1 |
| WO2020092528A1 (en) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity |
| CN113039185A (zh) * | 2018-11-09 | 2021-06-25 | 豪夫迈·罗氏有限公司 | 5-[6-[[3-(4,5,6,7-四氢吡唑并[4,3-c]吡啶-1-基)氮杂环丁烷-1-基]甲基]吗啉-4-基]喹啉-8-腈衍生物和类似化合物作为tlr7-9拮抗剂用于治疗系统性红斑狼疮 |
| CN109369571A (zh) * | 2018-12-04 | 2019-02-22 | 无锡市赛乐新材料科技有限公司 | 一种含氟取代的7-溴-4-醛基苯并噻二唑及其合成方法 |
| US10689360B1 (en) * | 2019-01-30 | 2020-06-23 | Insilico Medicine Ip Limited | TLR inhibitors |
| US11807622B2 (en) | 2019-01-30 | 2023-11-07 | Insilico Medicine Ip Limited | TLR 9 inhibitors |
| US11008303B2 (en) | 2019-01-30 | 2021-05-18 | Insilico Medicine Ip Limited | TLR 9 inhibitors |
| US12281119B2 (en) | 2019-02-07 | 2025-04-22 | Beigene, Ltd. | Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives as TLR7 agonist |
| WO2020178768A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| US12318403B2 (en) | 2019-03-07 | 2025-06-03 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2′3′-cyclic dinucleotides and prodrugs thereof |
| EP3935066A1 (en) | 2019-03-07 | 2022-01-12 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| JP2022081710A (ja) * | 2019-03-29 | 2022-06-01 | ユーティアイ リミテッド パートナーシップ | 関節リウマチを治療するためのｔ型カルシウムチャネル阻害剤の使用 |
| WO2020203609A1 (ja) * | 2019-03-29 | 2020-10-08 | 日本ケミファ株式会社 | 掻痒を治療するためのｔ型カルシウムチャネル阻害剤の使用 |
| JP7692838B2 (ja) * | 2019-04-09 | 2025-06-16 | エフ． ホフマン－ラ ロシュ アーゲー | 自己免疫疾患の治療のためのヘキサヒドロ－１Ｈ－ピラジノ［１，２－ａ］ピラジン化合物 |
| TW202210480A (zh) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TWI751517B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| EP3972695A1 (en) | 2019-05-23 | 2022-03-30 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
| CN112094224B (zh) * | 2019-06-18 | 2022-08-26 | 浙江医药股份有限公司新昌制药厂 | 一种带保护基的3-取代-5-氨基哌啶的制备方法 |
| WO2021034804A1 (en) | 2019-08-19 | 2021-02-25 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
| CN112430208A (zh) * | 2019-08-26 | 2021-03-02 | 东莞市东阳光仿制药研发有限公司 | 一种pf-06651600中间体的制备方法 |
| AR119821A1 (es) | 2019-08-28 | 2022-01-12 | Bristol Myers Squibb Co | Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t |
| JP2022546863A (ja) * | 2019-09-10 | 2022-11-09 | エフ．ホフマン－ラ ロシュ アーゲー | 自己免疫疾患の処置のための新規キノリン化合物 |
| JP2022547729A (ja) | 2019-09-16 | 2022-11-15 | エフ．ホフマン－ラ ロシュ アーゲー | 自己免疫疾患を治療するためのピペリジニルアミン化合物 |
| JP7398556B2 (ja) | 2019-09-30 | 2023-12-14 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｂｖワクチン及びｈｂｖを治療する方法 |
| EP4045485A1 (en) | 2019-10-18 | 2022-08-24 | The Regents Of The University Of California | 3-phenylsulphonyl-quinoline derivatives as agents for treating pathogenic blood vessels disorders |
| EP4051387B1 (en) * | 2019-10-31 | 2025-02-19 | F. Hoffmann-La Roche AG | Hydropyrazino[1,2-d][1,4]diazepine compounds for the treatment of autoimmune disease |
| EP4058452B1 (en) * | 2019-11-12 | 2025-07-09 | F. Hoffmann-La Roche AG | Hydropyrazino[1,2-b]isoquinoline compounds for the treatment of autoimmune disease |
| JP2023502087A (ja) * | 2019-11-19 | 2023-01-20 | エフ．ホフマン－ラ ロシュ アーゲー | 自己免疫疾患の処置のためのヒドロ－１Ｈ－ピロロ［１，２－ａ］ピラジン化合物 |
| JP2023502238A (ja) * | 2019-11-19 | 2023-01-23 | エフ．ホフマン－ラ ロシュ アーゲー | 自己免疫疾患の処置のためのトリアザトリサイクル化合物 |
| JP7649306B2 (ja) * | 2019-11-20 | 2025-03-19 | エフ． ホフマン－ラ ロシュ アーゲー | 自己免疫疾患の処置のためのスピロ（イソベンゾフラナゼチジン）化合物 |
| CN114728987B (zh) * | 2019-11-26 | 2024-08-02 | 豪夫迈·罗氏有限公司 | 用于治疗自身免疫性疾病的1,8-萘啶-2-酮化合物 |
| MX2022006466A (es) | 2019-11-28 | 2022-08-17 | Bayer Ag | Aminoquinolonas sustituidas como inhibidores de dgk alfa para la activacion inmune. |
| CN114761406B (zh) * | 2019-12-03 | 2024-04-19 | 豪夫迈·罗氏有限公司 | 用于治疗自身免疫性疾病的氢吡啶并[1,2-a]吡嗪化合物 |
| WO2021113765A1 (en) | 2019-12-06 | 2021-06-10 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome |
| JP7644121B2 (ja) | 2019-12-18 | 2025-03-11 | インターベット インターナショナル ベー． フェー． | アザインドール構造を含む駆虫剤化合物 |
| CN115175907B (zh) | 2019-12-23 | 2024-08-02 | 百时美施贵宝公司 | 可用作t细胞激活剂的经取代的哌嗪衍生物 |
| AR120823A1 (es) | 2019-12-23 | 2022-03-23 | Bristol Myers Squibb Co | Compuestos bicíclicos sustituidos útiles como activadores de células t |
| US12492172B2 (en) | 2019-12-23 | 2025-12-09 | Bristol-Myers Squibb Company | Substituted quinazolinyl compounds useful as T cell activators |
| WO2021188959A1 (en) | 2020-03-20 | 2021-09-23 | Gilead Sciences, Inc. | Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
| EP4149463A1 (en) * | 2020-05-14 | 2023-03-22 | Merck Healthcare KGaA | Tlr7/8 antagonists for the treatment of coronavirus infections |
| CN116507331A (zh) * | 2020-06-15 | 2023-07-28 | 默克专利有限公司 | Tlr7/8拮抗剂及其用途 |
| US11857551B1 (en) | 2020-07-10 | 2024-01-02 | Ting Therapeutics Llc | Methods for the prevention and treatment of hearing loss |
| TW202214632A (zh) * | 2020-07-27 | 2022-04-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 吲哚稠環類衍生物、其製備方法及其在醫藥上的應用 |
| WO2022028389A1 (zh) * | 2020-08-03 | 2022-02-10 | 江苏恒瑞医药股份有限公司 | 稠三环类衍生物、其制备方法及其在医药上的应用 |
| CN114057754B (zh) * | 2020-08-07 | 2023-05-16 | 江苏恒瑞医药股份有限公司 | 含氮桥环类衍生物、其制备方法及其在医药上的应用 |
| MA66139B1 (fr) | 2020-09-09 | 2025-09-30 | Crinetics Pharmaceuticals, Inc. | Formulations d'un modulateur de somatostatine |
| WO2022067462A1 (en) * | 2020-09-29 | 2022-04-07 | Beigene (Beijing) Co., Ltd. | Process for preparing inhibitors of kras g12c |
| KR102513463B1 (ko) * | 2020-11-26 | 2023-03-29 | 주식회사 에스앤케이테라퓨틱스 | 엔도솜 톨-유사 수용체를 제어하는 신규 소분자 화합물 및 이를 이용한 자가면역질환 치료제 |
| CA3200155A1 (en) | 2020-11-26 | 2022-06-02 | Xiaomin Zhang | Fused tricyclic compound, preparation method therefor and application thereof in medicine |
| CN115109032B (zh) * | 2021-03-18 | 2023-09-05 | 成都百裕制药股份有限公司 | 喹啉衍生物及其在医药上的应用 |
| WO2022221642A1 (en) | 2021-04-16 | 2022-10-20 | Gilead Sciences, Inc. | Thienopyrrole compounds |
| WO2022241134A1 (en) | 2021-05-13 | 2022-11-17 | Gilead Sciences, Inc. | COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS |
| CN117377671A (zh) | 2021-06-23 | 2024-01-09 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
| CA3222277A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| AU2022297367B2 (en) | 2021-06-23 | 2025-04-10 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| IL309378A (en) | 2021-06-23 | 2024-02-01 | Gilead Sciences Inc | Diacylglyercol kinase modulating compounds |
| EP4398989A1 (en) | 2021-09-10 | 2024-07-17 | Gilead Sciences, Inc. | Thienopyrrole compounds |
| CN115160296B (zh) * | 2022-08-08 | 2024-05-28 | 西安市第五医院 | 一种n-取代喹啉-4-胺类化合物及其制备、药物组合物和应用 |
| CN115650881B (zh) * | 2022-09-06 | 2025-01-17 | 浙江医药股份有限公司新昌制药厂 | 一种利用微反应器合成喹诺酮类化合物中间体的工艺方法 |
| WO2024153063A1 (zh) | 2023-01-18 | 2024-07-25 | 苏州科睿思制药有限公司 | Enpatoran的晶型及其制备方法和用途 |
| WO2025201636A1 (en) | 2023-03-31 | 2025-10-02 | Syngenta Crop Protection Ag | Pesticidally-active 2,2-dihalocyclopropyl compounds |
| WO2025214612A1 (en) | 2023-04-14 | 2025-10-16 | Syngenta Crop Protection Ag | Pesticidally-active 2,2-dihalocyclopropyl compounds |
| WO2025261608A1 (en) | 2023-06-29 | 2025-12-26 | Syngenta Crop Protection Ag | Pesticidally-active 2,2-dihalocyclopropyl compounds |
| WO2026002399A1 (en) | 2023-07-07 | 2026-01-02 | Syngenta Crop Protection Ag | Pesticidally-active 2,2-dihalocyclopropyl compounds |
| WO2025032190A1 (en) | 2023-08-09 | 2025-02-13 | Merck Patent Gmbh | Crystalline form a1 of 5-((3r,55)-3-amino-5- trifluoromethyl-piperidin-1-yl)-quinoline-8-carbonitrile hcl |
| WO2025032195A1 (en) | 2023-08-09 | 2025-02-13 | Merck Patent Gmbh | Crystalline form h1 of 5-((3r,55)-3-amino-5- trifluoromethyl-piperidin-1-yl)-quinoline-8-carbonitrile hemihydrate |
| WO2025032197A1 (en) | 2023-08-09 | 2025-02-13 | Merck Patent Gmbh | Crystalline form of 5-((3r,5s)-3-amino-5-trifluoromethyl-piperidin-1-yl)-quinoline-8-carbonitrile |
| WO2025160132A1 (en) * | 2024-01-23 | 2025-07-31 | Maplight Therapeutics, Inc. | Gpr6 inverse agonists |
| WO2025240246A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240242A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240244A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection |
| US20250345389A1 (en) | 2024-05-13 | 2025-11-13 | Gilead Sciences, Inc. | Combination therapies |
| WO2025252553A1 (en) | 2024-06-04 | 2025-12-11 | Syngenta Crop Protection Ag | Pesticidally-active 2,2-dihalocyclopropyl compounds |
| WO2025252556A1 (en) | 2024-06-05 | 2025-12-11 | Syngenta Crop Protection Ag | Pesticidally-active 2,2-dihalocyclopropyl compounds |
| EP4667451A1 (en) | 2024-06-21 | 2025-12-24 | Syngenta Crop Protection AG | Pesticidally-active 2,2-dihalocyclopropyl compounds |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1020252A (en) * | 1911-04-26 | 1912-03-12 | Arthur H Bell | Brooder. |
| US1016829A (en) * | 1911-05-19 | 1912-02-06 | Abraham Hurwitz | Device for setting pallet-jewels. |
| US1227293A (en) * | 1914-04-10 | 1917-05-22 | Charles H Morison | Safety-catch for cuff-buttons. |
| US1271680A (en) * | 1918-01-15 | 1918-07-09 | Emanuel W Dunn | Heater. |
| US1367747A (en) * | 1919-05-07 | 1921-02-08 | George B Keplinger | Bath-brush |
| DE812911C (de) | 1945-03-12 | 1951-09-06 | Rhone Poulenc Sa | Verfahren zur Herstellung von neuen substituierten Derivaten des Piperidins |
| CH578535A5 (en) | 1973-05-11 | 1976-08-13 | Ciba Geigy Ag | Quinoline-3-carboxylic acid derivs - with e.g. analgesic, antinociceptive, antiinflammatory and antiallergic props |
| US4933447A (en) * | 1987-09-24 | 1990-06-12 | Ss Pharmaceutical Co., Ltd. | Quinoline derivatives |
| FR2798656B1 (fr) | 1999-09-17 | 2004-12-17 | Aventis Pharma Sa | Derives de la quinolyl propyl piperidine, leur preparation et les compositions qui les contiennent |
| HUP0402124A2 (hu) | 2001-11-14 | 2005-02-28 | Merck Patent Gmbh | Pszichofarmakológiában alkalmazható pirazolszármazékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények |
| GB0206033D0 (en) | 2002-03-14 | 2002-04-24 | Pfizer Ltd | Compounds useful in therapy |
| WO2003105850A1 (en) | 2002-06-18 | 2003-12-24 | Abbott Laboratories | 2-aminoquinolines as melanin concentrating hormone receptor antagonists |
| US7649001B2 (en) | 2002-08-12 | 2010-01-19 | Takeda Pharmaceutical Company Limited | Fused benzene derivative and use |
| AU2003274551A1 (en) | 2002-11-12 | 2004-06-03 | Pfizer Products Inc. | Quinoline derivatives |
| GB0227240D0 (en) | 2002-11-21 | 2002-12-31 | Glaxo Group Ltd | Compounds |
| GB0229281D0 (en) * | 2002-12-16 | 2003-01-22 | Novartis Ag | Organic compounds |
| US20050124625A1 (en) * | 2003-10-21 | 2005-06-09 | Salvati Mark E. | Piperazine derivatives and their use as modulators of nuclear hormone receptor function |
| US20070225308A1 (en) | 2004-03-15 | 2007-09-27 | Kyowa Hakko Kogyo Co.,Ltd. | 2-Amino Quinazoline Derivative |
| US20060211752A1 (en) | 2004-03-16 | 2006-09-21 | Kohn Leonard D | Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression |
| US20070004679A1 (en) | 2004-05-17 | 2007-01-04 | Nathalie Schlienger | Androgen receptor modulators and methods of treating disease using the same |
| CN101248069A (zh) | 2004-05-17 | 2008-08-20 | 阿卡蒂亚药品公司 | 雄激素受体调节剂及用其治疗疾病的方法 |
| WO2006009245A1 (ja) | 2004-07-23 | 2006-01-26 | Tanabe Seiyaku Co., Ltd. | 含窒素縮合二環式化合物 |
| CN101023083A (zh) * | 2004-07-23 | 2007-08-22 | 田边制药株式会社 | 含氮的稠合双环化合物 |
| JP2006056882A (ja) * | 2004-07-23 | 2006-03-02 | Tanabe Seiyaku Co Ltd | ピラゾロピリミジン化合物 |
| US20090264415A2 (en) * | 2004-12-30 | 2009-10-22 | Steven De Jonghe | Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for medical treatment |
| GB0510810D0 (en) | 2005-05-26 | 2005-06-29 | Novartis Ag | Organic compounds |
| GB0526042D0 (en) | 2005-12-21 | 2006-02-01 | Syngenta Participations Ag | Chemical compounds |
| JPWO2007097289A1 (ja) | 2006-02-20 | 2009-07-16 | 武田薬品工業株式会社 | 新規医薬 |
| ES2648388T3 (es) * | 2006-08-23 | 2018-01-02 | Kudos Pharmaceuticals Limited | Derivados de 2-metilmorfolin pirido-, pirazo- y pirimido-pirimidina como inhibidores de mTOR |
| EP1903038A1 (de) * | 2006-09-07 | 2008-03-26 | Bayer Schering Pharma Aktiengesellschaft | N-(1-Hetaryl-piperidin-4-yl)-(het)arylamide als EP2-Rezeptor Modulatoren |
| WO2008037681A1 (en) | 2006-09-26 | 2008-04-03 | Glaxo Group Limited | 5-{2-[4-(2-methyl-5-quinolinyl)-l-piperidinyl] ethyl} quinolinone derivatives as 5ht1a receptor modulators for treating sexual dysfunction, cognition impairement, psychotic disorders, anxiety, depression, etc. |
| CL2008001002A1 (es) | 2007-04-11 | 2008-10-17 | Actelion Pharmaceuticals Ltd | Compuestos derivados de oxazolidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para preparar un medicamento para tratar una infeccion bacteriana. |
| DK2164825T3 (da) | 2007-06-05 | 2014-07-14 | Sanofi Sa | Di(hetero)arylcyclohexanderivater, deres fremstilling, deres anvendelse og terapeutiske præparater, der omfatter disse |
| US20110237600A1 (en) | 2008-05-12 | 2011-09-29 | Amnestix, Inc. | Compounds for improving learning and memory |
| US20110201599A1 (en) | 2008-07-03 | 2011-08-18 | Exelixis, Inc. | CDK Modulators |
| CA2735779A1 (en) * | 2008-09-02 | 2010-03-11 | Matthew Burger | Bicyclic kinase inhibitors |
| EP2352732B1 (en) | 2008-12-01 | 2013-02-20 | Merck Patent GmbH | 2,5-DIAMINO-SUBSTITUTED PYRIDO[4, 3-d]PYRIMIDINES AS AUTOTAXIN INHIBITORS AGAINST CANCER |
| JP2012517428A (ja) | 2009-02-11 | 2012-08-02 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Ｔｏｌｌ様レセプター調節因子および疾患の処置 |
| EP2401275B1 (en) * | 2009-02-24 | 2013-07-24 | Respiratorius AB | Naphthyridine derivatives having bronchodilating activity |
| CA2768236C (en) | 2009-07-16 | 2018-05-22 | Mallinckrodt Llc | (+)-morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof |
| US20120214803A1 (en) * | 2011-02-18 | 2012-08-23 | Vifor (International) Ag | Novel Sulfonaminoquinoline Hepcidin Antagonists |
| WO2013060881A1 (en) | 2011-10-27 | 2013-05-02 | Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg | Pyridopyrimidines and their therapeutic use |
| WO2014086453A1 (en) | 2012-12-07 | 2014-06-12 | Merck Patent Gmbh | Azaheterobicyclic compounds |
| TWI642657B (zh) | 2013-06-26 | 2018-12-01 | 艾伯維有限公司 | 作為ｂｔｋ抑制劑的初級甲醯胺 |
| TWI529171B (zh) * | 2013-07-29 | 2016-04-11 | 赫孚孟拉羅股份公司 | １，７－萘啶衍生物 |
| JP6559132B2 (ja) | 2013-08-23 | 2019-08-14 | ニューファーマ， インコーポレイテッド | ある特定の化学的実体、組成物および方法 |
| CN105636945B (zh) * | 2013-10-14 | 2017-11-17 | 卫材R&D管理有限公司 | 选择性取代的喹啉化合物 |
| LT3057964T (lt) * | 2013-10-14 | 2020-02-25 | Eisai R&D Management Co., Ltd. | Selektyviai pakeistieji chinolino junginiai |
| CN104557913B (zh) | 2013-10-28 | 2017-02-08 | 上海汇伦生命科技有限公司 | 吡啶并嘧啶类化合物，其制备方法和用途 |
| CN105992766A (zh) | 2013-12-13 | 2016-10-05 | 武田药品工业株式会社 | 作为tlr抑制剂的吡咯并[3,2-c]吡啶衍生物 |
| WO2015092592A1 (en) | 2013-12-17 | 2015-06-25 | Pfizer Inc. | Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors |
| WO2015120111A2 (en) | 2014-02-05 | 2015-08-13 | Stereokem, Inc. (Usa) | Expedient synthesis of sitagliptin |
| CN104945377A (zh) | 2014-03-24 | 2015-09-30 | 南京明德新药研发股份有限公司 | 作为smo抑制剂的喹啉衍生物 |
| RU2695815C9 (ru) | 2014-03-24 | 2019-10-28 | Гуандун Чжуншэн Фармасьютикал Ко., Лтд | Хинолиновые производные в качестве ингибиторов smo |
| MX377916B (es) | 2014-04-22 | 2025-03-10 | Hoffmann La Roche | Compuestos 4-amino-imidazoquinolina. |
| GB201411236D0 (en) | 2014-06-25 | 2014-08-06 | Takeda Pharmaceutical | Novel compounds |
| EP3215156B1 (en) | 2014-11-03 | 2025-09-24 | Iomet Pharma Ltd. | Inhibitors of tryptophan-2,3-dioxygenase or indoleamine-2,3-dioxygenase |
| UY36390A (es) | 2014-11-05 | 2016-06-01 | Flexus Biosciences Inc | Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen |
| WO2016087593A1 (en) | 2014-12-05 | 2016-06-09 | Syngenta Participations Ag | Novel fungicidal quinolinylamidines |
| MA41169A (fr) | 2014-12-17 | 2017-10-24 | Acraf | Composés antibactériens à large spectre d'activité |
| JP2018525345A (ja) | 2015-07-01 | 2018-09-06 | ノースウェスタン ユニバーシティ | 置換キナゾリン化合物及びグルコセレブロシダーゼ活性の調節のためのその使用 |
| WO2017031427A1 (en) | 2015-08-19 | 2017-02-23 | 3-V Biosciences, Inc. | COMPOUNDS AND METHODS FOR INHIBITING mTOR |
| MY196319A (en) | 2015-12-17 | 2023-03-24 | Merck Patent Gmbh | Polycyclic TLR7/8 Antagonists and use Thereof in the Treatment of Immune Disorders |
| CN109563075B (zh) | 2016-08-08 | 2022-09-30 | 默克专利股份公司 | Tlr7/8拮抗剂及其用途 |
| CN118894840A (zh) | 2017-07-18 | 2024-11-05 | 默克专利股份公司 | Tlr7/8拮抗剂及其用途 |
| BR112020012329A2 (pt) | 2017-12-19 | 2020-11-24 | Merck Patent Gmbh | antagonistas de tlr7/8 e usos dos mesmos |
| CN112513024A (zh) | 2018-07-31 | 2021-03-16 | 默克专利股份公司 | Tlr7/8拮抗剂及其用途 |
-
2016
- 2016-12-16 MY MYPI2018702111A patent/MY196319A/en unknown
- 2016-12-16 HR HRP20240355TT patent/HRP20240355T1/hr unknown
- 2016-12-16 KR KR1020257009400A patent/KR20250043596A/ko active Pending
- 2016-12-16 SM SM20240141T patent/SMT202400141T1/it unknown
- 2016-12-16 MX MX2021006804A patent/MX2021006804A/es unknown
- 2016-12-16 PL PL21172996.7T patent/PL3889145T3/pl unknown
- 2016-12-16 EP EP21172998.3A patent/EP3889146A1/en active Pending
- 2016-12-16 NZ NZ742476A patent/NZ742476A/en unknown
- 2016-12-16 CA CA3005766A patent/CA3005766A1/en active Pending
- 2016-12-16 ES ES21172996T patent/ES2981114T3/es active Active
- 2016-12-16 UA UAA201807881A patent/UA124802C2/uk unknown
- 2016-12-16 EP EP21172996.7A patent/EP3889145B1/en active Active
- 2016-12-16 LT LTEP21172996.7T patent/LT3889145T/lt unknown
- 2016-12-16 SG SG10202001146PA patent/SG10202001146PA/en unknown
- 2016-12-16 US US15/381,406 patent/US10399957B2/en active Active
- 2016-12-16 KR KR1020187018717A patent/KR102787063B1/ko active Active
- 2016-12-16 HU HUE21172996A patent/HUE066591T2/hu unknown
- 2016-12-16 CN CN201680081793.1A patent/CN108699032B/zh active Active
- 2016-12-16 MY MYPI2023001174A patent/MY210123A/en unknown
- 2016-12-16 RS RS20240342A patent/RS65319B1/sr unknown
- 2016-12-16 SI SI201631813T patent/SI3889145T1/sl unknown
- 2016-12-16 CN CN202110952016.2A patent/CN113603675A/zh active Pending
- 2016-12-16 ES ES16840344T patent/ES2883285T3/es active Active
- 2016-12-16 WO PCT/US2016/067112 patent/WO2017106607A1/en not_active Ceased
- 2016-12-16 DK DK21172996.7T patent/DK3889145T3/da active
- 2016-12-16 MX MX2018006637A patent/MX385424B/es unknown
- 2016-12-16 JP JP2018531479A patent/JP6882299B2/ja active Active
- 2016-12-16 EP EP16840344.2A patent/EP3390389B1/en active Active
- 2016-12-16 AU AU2016371014A patent/AU2016371014B2/en active Active
- 2016-12-16 SG SG11201804170RA patent/SG11201804170RA/en unknown
- 2016-12-16 FI FIEP21172996.7T patent/FI3889145T3/fi active
- 2016-12-16 PT PT211729967T patent/PT3889145T/pt unknown
- 2016-12-19 TW TW110137731A patent/TWI804003B/zh active
- 2016-12-19 TW TW112116054A patent/TWI886474B/zh active
- 2016-12-19 TW TW105142060A patent/TWI736566B/zh active
-
2018
- 2018-05-17 PH PH12018501068A patent/PH12018501068A1/en unknown
- 2018-05-21 ZA ZA2018/03367A patent/ZA201803367B/en unknown
- 2018-05-31 IL IL279751A patent/IL279751B/en active IP Right Grant
- 2018-05-31 IL IL259751A patent/IL259751B/en active IP Right Grant
- 2018-06-15 CL CL2018001624A patent/CL2018001624A1/es unknown
-
2019
- 2019-07-10 US US16/507,870 patent/US10544122B2/en active Active
- 2019-11-26 US US16/696,503 patent/US10696649B2/en active Active
-
2020
- 2020-04-28 US US15/929,348 patent/US10947213B1/en active Active
- 2020-12-19 US US17/128,021 patent/US11629134B2/en active Active
- 2020-12-24 IL IL279752A patent/IL279752B2/en unknown
- 2020-12-24 IL IL279751A patent/IL279751A/en active IP Right Grant
-
2021
- 2021-02-10 JP JP2021019843A patent/JP7317878B2/ja active Active
- 2021-08-17 AU AU2021218041A patent/AU2021218041B2/en active Active
-
2023
- 2023-03-06 US US18/179,211 patent/US20230303514A1/en not_active Abandoned
- 2023-07-19 JP JP2023117597A patent/JP2023126574A/ja active Pending
- 2023-12-18 AU AU2023285714A patent/AU2023285714A1/en not_active Abandoned
-
2024
- 2024-10-23 US US18/923,917 patent/US20250059157A1/en active Pending
-
2025
- 2025-11-28 AU AU2025271466A patent/AU2025271466A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018537501A5 (enExample) | ||
| JP2019527718A5 (enExample) | ||
| JP2020537671A5 (enExample) | ||
| HRP20200179T1 (hr) | Spojevi heteroarila kao inhibitori irak i njihova uporaba | |
| RU2019105719A (ru) | Антагонисты tlr7/8 и их применение | |
| HRP20240355T1 (hr) | 8-cijano-5-piperidino-kinolini kao tlr7/8 antagonisti i njihova upotreba u liječenju imunoloških poremećaja | |
| TWI776994B (zh) | 經碸吡啶烷基醯胺取代之雜芳基化合物 | |
| RU2020123151A (ru) | Антагонисты tlr7/8 и их применение | |
| RU2020115596A (ru) | ПИРИМИДИНОВЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ TBK/IKKε И ИХ ПРИМЕНЕНИЯ | |
| JP2017524733A5 (enExample) | ||
| JP2017530959A5 (enExample) | ||
| JP2015518903A5 (enExample) | ||
| RU2017101829A (ru) | Пиразоловые соединения в качестве модуляторов fshr и пути их применения | |
| JP2017538689A5 (enExample) | ||
| JP2017509586A5 (enExample) | ||
| JP2018536634A5 (enExample) | ||
| RU2019131017A (ru) | Соединения гетероарила в качестве ингибиторов btk и их применение | |
| JP2020517611A5 (enExample) | ||
| JP2018538248A5 (enExample) | ||
| JP2017514910A5 (enExample) | ||
| JP2017502092A5 (enExample) | ||
| JP2016529306A5 (enExample) | ||
| HRP20171763T1 (hr) | Derivati piridin-4-ila | |
| RU2017105133A (ru) | Индолизиновые производные, которые применяют при нейродегенеративных заболеваниях | |
| JP2017520538A5 (enExample) |